Acetylcholine is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Acetylcholine (ACh) is a neurotransmitter essential for synaptic transmission in both the central and peripheral nervous systems. It mediates neuromuscular junction signaling, autonomic function, and cognitive processes including learning, memory, attention, and arousal. The cholinergic[@whitehouse1982] system is profoundly affected in [Alzheimer's Disease][mesulam1983], where degeneration of basal forebrain cholinergic[@whitehouse1982] neurons is a hallmark pathological feature. [@mesulam1983]
This relationship forms the basis of the cholinergic[@whitehouse1982] hypothesis -- the first major neurochemical theory of [@greig2005]
Alzheimer's Disease[@mesulam1983] -- and led to the development of cholinesterase inhibitors as [@hasselmo2006]
the first approved symptomatic treatments (Bartus et al., 1982; Francis et al., [@birks2006]
1999) (Hampel et al., 2018). [@wang2000]
Acetylcholine is a quaternary ammonium ester: [@scarpa2020]
ACh is synthesized in cholinergic[@whitehouse1982] neurons through a single enzymatic step: [@hampel2018]
Butyrylcholinesterase (BuChE), expressed in glia and plasma, provides a secondary degradation pathway that becomes more important as disease progresses and AChE levels decline (Greig et al., 2005) (Francis et al., 1999).
The BFCS provides the primary cholinergic[@whitehouse1982] innervation to the cerebral cortex and hippocampus
and is critical for cognitive function: (Mesulam et al., 1983)
Large aspiny cholinergic[@whitehouse1982] interneurons in the striatum modulate dopaminergic
signaling and are relevant to Parkinson's disease and Huntington's disease (Whitehouse et al.,
1982).
ACh acts through two major receptor superfamilies with distinct pharmacology and signaling:
| Subtype | G Protein | CNS Distribution | Key Functions |
|---|---|---|---|
| M1 | Gq/11 | cortex, hippocampus | Memory, attention, cortical plasticity |
| M2 | Gi/o | Brainstem, thalamus, presynaptic terminals | Autoreceptor; inhibits ACh release |
| M3 | Gq/11 | Hypothalamus, salivary glands | Smooth muscle, glandular secretion |
| M4 | Gi/o | Striatum, cortex | Modulates dopamine release; motor control |
| M5 | Gq/11 | Substantia nigra, VTA | Modulates dopamine neuron activity |
M1 receptors are the primary postsynaptic target in the cortex and hippocampus and are key mediators of cholinergic[@greig2005]
and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537]:1237-1239.
doi:10.1126/science.7058341" data-ref-title="Price DL, Struble RG, et al. Alzheimer's Disease[@greig2005]
and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537]:1237-1239.
doi:10.1126/science.7058341" data-ref-authors="[Whitehouse PJ" data-ref-journal="Price DL,
Struble RG, et al. Alzheimer's Disease[@greig2005] and senile dementia: loss of neurons in the basal forebrain. Science" data-ref-year="1982"
data-ref-url="https://pubmed.ncbi.nlm.nih.gov/7058325/" title="[Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's Disease[@greig2005] and
senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537]:1237-1239.
doi:10.1126/science.7058341">[@whitehouse1982] cognitive enhancement. M1 positive allosteric
modulators (PAMs) are under investigation as potential AD therapeutics (Scarpa et al., 2020).
| Subtype | Composition | CNS Distribution | Key Functions |
|---|---|---|---|
| alpha4-beta2 | (alpha4)2(beta2)3 or (alpha4)3(beta2)2 | Widespread; thalamus, cortex | High-affinity nicotine binding; attention |
| alpha7 | (alpha7)5 | hippocampus, cortex, microglia. |
First articulated by Bartus et al. (1982) and subsequently refined, the cholinergic[@whitehouse1982] hypothesis proposes that degeneration of basal
forebrain cholinergic[@whitehouse1982] neurons and the resulting cortical/hippocampal
cholinergic[@whitehouse1982] deficit is a primary contributor to cognitive decline
in AD (Bartus et al., 1982). For a detailed discussion, see Cholinergic Hypothesis in
Alzheimer's Disease.
AD is characterized by severe and progressive cholinergic[@whitehouse1982] deficits:
Cholinergic dysfunction intersects with multiple AD pathological processes:
Cholinesterase inhibitors remain the primary symptomatic treatment for AD:
| Drug | Target | Formulation | Indication |
|---|---|---|---|
| Donepezil (Aricept) | Selective AChE | Oral (QD) | Mild-severe AD |
| Rivastigmine (Exelon) | AChE + BuChE | Oral, transdermal | Mild-moderate AD, PDD |
| Galantamine (Razadyne) | AChE + alpha7 nAChR PAM | Oral (ER) | Mild-moderate AD |
These provide modest but clinically meaningful symptomatic benefits in cognition, function, and behavior. They do not modify disease progression (Birks, 2006).
The study of Acetylcholine has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
PMID:7058325
2. [Mesulam MM, Mufson EJ, Levey AI, et al., Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis, and substantia innominata. J Comp Neurol. 1983;214(2):170-197. doi:10.1002/cne.902140206 (1983)
PMID:15853536
PMID:17011181
PMID:16437532
6. [Wang HY, Lee DH, D'Andrea MR, et al, beta-Amyloid(1-42] binds to alpha7 nicotinic acetylcholine[1] receptor with high affinity (2000)]([PMID:10681545)(https://pubmed.ncbi.nlm.nih.gov/10681545/))
7. [Unknown, Scarpa M, Bhattacharyya S, Bhatt S. Muscarinic M1 receptor positive allosteric modulators: bridging the gap between theoretical models and clinical applications. ACS Chem Neurosci. 2020;11(9):1269-1283. doi:10.1021/acschemneuro.0c00088 (2020)
PMID:29850777
PMID:26813123